Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | AI Infrastructure · LTA · HBM Demand / 2026-06-09 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | DRAM Supply-Demand · AI Infrastructure Finance · Valuation Re-rating / 2026-08-14 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | ESS Revenue Surge · 4Q26 Turnaround · Physical AI Expansion with 46-Series & All-Solid-State / 2026-02-03 Research
  • [IR] SK hynix (000660 / SKHY) – Q1 2024 Earnings Presentation / 2024-04-25 IR Room
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | NAND Pricing · Fab Utilization · Earnings Upgrades / 2026-01-07 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Readout · ABL111 Phase 3 · Grabody B Expansion / 2026-04-07 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Big Tech Backlogs · Memory Supply Tightness · Earnings Growth / 2026-07-14 Research

[Research] Hanwha Ocean (042660) – Hanwha | Merchant Margin Surprise · High-Price Mix Expansion · Special Ship Fixed-Cost Absorption / 2026-04-28

Posted on April 28, 2026August 22, 2026 By ksb220805@gmail.com

Brokerage : Hanwha Investment & Securities

Analyst : Seongjo Bae

Investment Rating : Buy (Maintained)

Target Price : KRW 175,000 (Raised)

Core Momentum : Substantial merchant margin surprise driven by the revenue recognition of high-price post-2024 orders and structural cost improvements across non-LNG vessel types, alongside upcoming defense milestones including KDDX order intake and Canadian CPSP preferred bidder selection

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: Buy Maintained, Target Price raised to KRW 175,000 by applying the existing Target P/E of 27x to revised 2027E EPS (Current Price: KRW 133,500 as of April 27, 2026; Upside potential: 31.1%)
  • 1Q26 Earnings Summary: Revenue came in at KRW 3.21 trillion (+2.1% YoY) and Operating Profit stood at KRW 441.1 billion (+70.6% YoY, OPM 13.7%), beating market consensus by 17.6% on operating profit.
  • Key Forecast Financials (2025 → 2026E → 2027E):
    • Revenue: KRW 12.78 trillion → KRW 13.42 trillion → KRW 15.41 trillion
    • Operating Profit: KRW 1.17 trillion → KRW 1.72 trillion → KRW 2.22 trillion
    • EBITDA: KRW 1.40 trillion → KRW 2.03 trillion → KRW 2.63 trillion
    • Net Profit (Controlling): KRW 1.25 trillion → KRW 1.58 trillion → KRW 1.99 trillion
    • EPS: KRW 4,066 → KRW 5,144 → KRW 6,483
    • Net Debt: KRW 5.00 trillion → KRW 4.71 trillion → KRW 3.86 trillion
    • PER: 32.8x → 26.0x → 20.6x
    • PBR: 6.6x → 5.3x → 4.2x
    • ROE: 22.6% → 22.6% → 22.7%
    • EV/EBITDA: 32.8x → 22.5x → 17.1x

🚀 2. [Market Opportunities & Business Outlook]

  • Merchant Division Margin Outperformance: In 1Q26, the merchant shipbuilding division posted revenue of KRW 2.79 trillion (+8.8% YoY) and operating profit of KRW 502.1 billion (OPM 18.0%), offsetting fixed overhead from other divisions (such as the offshore energy plant unit’s operating loss of KRW 73.9 billion). Profitability was propelled by a confluence of drivers: expanded recognition of post-2024 high-price orders, favorable FX movements, cost structure optimization in non-LNG vessel segments, and early delivery efficiency via productivity improvements without material one-offs.
  • Merchant Sales Mix Dynamics: While 2026 LNGC revenue exposure will moderate slightly to ~50% due to reduced lower-priced Qatar Phase 1 volume, average recognized vessel prices are expected to rise. Projected annual revenue share by order vintage stands at 10% for 2022, 20% for 2023, 40% for 2024, and 30% for 2025; steady early deliveries in 2Q–4Q will support high double-digit merchant margins.
  • Special Ship Operations & Defense Catalysts: In 1Q26, the special ship division logged revenue of KRW 318.3 billion (+4.9% YoY) and an operating loss of KRW 20.8 billion (OPM -6.5%), reflecting ongoing builds for Changbogo-III Batch-II ship #2 and Ulsan-class Batch-III ships #5/6. Improving dock utilization via the KDDX contract within the year is essential to absorb fixed costs, while remaining C/Os from US MRO projects are slated for recognition in 2Q. The Canadian CPSP submarine program is a major catalyst, with preferred bidder selection slated for 1H26 and definitive contract signing in 2028.

📝 Editor’s Comment (Perspective)

The analyst views Hanwha Ocean as a shipbuilder demonstrating a fundamental margin breakthrough in its commercial shipbuilding division through the execution of high-price contract vintages and non-LNG cost restructuring, utilizing these core cash flows to offset fixed overhead in its naval business while upgrading earnings estimates. This perspective emphasizes the structural, recurring nature of the commercial margin expansion and the strategic valuation upside tied to upcoming defense milestones such as KDDX and the Canadian CPSP submarine tender.

To evaluate whether this investment thesis continues to materialize, key verification points include whether merchant operating margins remain near the 18% level as post-2024 order deliveries ramp up, the earnings recognition of remaining US naval MRO change orders in 2Q, and definitive tender milestones including the domestic KDDX contract and the 1H26 preferred bidder announcement for the Canadian CPSP submarine program. These factors can be monitored through future quarterly earnings releases, official IR materials, regulatory filings, and periodic financial reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Shipbuilding

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Mirae Asset | Agentic AI · Server CPU · LPDDR / 2026-04-28
Next Post: [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28

Related Posts

  • [Research] Samsung Electro-Mechanics (009150) – SK Securities | Global Tier-1 Multiples · Passive-Substrate Synergy · Embedded & Si-Cap / 2026-05-26 Research
  • [Research] Alteogen (196170) – Shinhan Securities | First UK Patent Ruling Favors Merck · Positive Read-across to Global Disputes · Pipeline Out-Licensing Ahead / 2026-02-23 Research
  • [Research] Samsung Biologics (207940) – Kyobo Securities | H2 Revenue Recognition · Modality Diversification · Earnings Growth / 2026-07-24 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Plant 5 Operation · Fixed-Cost Operating Leverage · Plant 6 Expansion / 2026-05-19 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Rockville Ramp-up · Business Scale Expansion · Revenue Visibility / 2026-07-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Cycle / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | HBM4 · Product Mix · LTA / 2026-07-30 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Hypothetical SDC Stake Monetization · North American ESS Acceleration · Valuation Appeal / 2026-01-19 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | Memory Pricing · Long-Term Contracts · HBM4 / 2026-01-14 Research
  • [Research] Samsung Biologics (207940) – iM Securities | US Site Operation · K-CDMO Policy Support · Order Pipeline Optimization / 2026-04-23 Research
  • [Research] Alteogen (196170) – Hana Securities | New ALT-B4 Deal Signed · Qlex Prescription Surge · SC Conversion Acceleration / 2026-08-06 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Cycle · Customer Prepayments · Server Demand / 2026-08-11 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 & Rockville Ramp-up · Guidance Upside · 4Q Earnings Concentration / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme